GSK3B and Alzheimer disease: GLP‐1 receptor agonists (e.g., exenatide, liraglutide, lixisenatide, semaglutide, dulaglutide) improve insulin signaling, reduce Aβ and tau pathology, modulate MAPKs and GSK‐3β, decrease neuroinflammation, and restore cognition in Alzheimer's disease animal models, showing strong neuroprotective potential [76, 77, 78].